Soria Jiménez, Luis (Date of defense: 2023-02-17)
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...
Suárez Olmos, Jesús (Date of defense: 2023-11-30)
Several studies support the contribution of antibody-dependent NK cell cytotoxicity (ADCC) to the clinical efficacy of anti-HER2 therapeutic antibodies in HER2-positive breast cancer. Novel anti-HER2 ...